Oncology
Since 2023, we have focused on developing therapies for cancers that remain the most difficult to treat, including rare and immunologically-driven malignancies. Cancer continues to be a leading global health challenge, with over 19 million people diagnosed each year and nearly 10 million deaths annually. Our approach integrates translational research, biomarker-driven strategies, and precision medicine to accelerate the development of innovative therapies. By targeting the underlying biology of tumors and leveraging novel immuno-oncology approaches, we aim to improve survival, restore function, and provide hope to patients facing limited treatment options.
Our Approach
Leveraging precision medicine, translational research, and biomarker-driven strategies, the focus is on advancing therapies from discovery to clinical development. Efforts span both common and rare blood cancers as well as immuno-oncology targets, aiming to improve survival, function, and quality of life for patients in need.
Innovative Research
Our research spans early discovery through late-stage clinical trials, exploring novel mechanisms that target tumor growth, the immune system, and resistance pathways. At Genventis, we are committed to bringing transformative therapies to patients who currently have few options, advancing hope and outcomes through science-driven innovation.
Living with Cancer’s disease: Larry’s story
Larry was diagnosed with an aggressive form of cancer that quickly disrupted his daily life and independence. Like millions of others worldwide, he faced the physical, emotional, and practical challenges of managing a serious illness. Through access to innovative therapies and clinical research, Larry found hope in treatments designed to address both his disease and its symptoms. His journey highlights the urgent need for continued development of therapies that not only extend life but also improve quality of life for patients and their families.
Facts and Figure
The impact of cancer worldwide
Cancer cases
Mortality & Survival Trend
~19.3M
~18%
new cancer cases were diagnosed in 2022, and about 53.5 million people were living with a cancer diagnosis within the previous 5 years
of global cancer deaths are due to lung cancer, the leading killer. Among men, lung cancer causes the most deaths, while among women, breast cancer is the deadliest.
Our focus on cancer research and treatments
We work with urgency to pursue breakthrough science to not only prolong lives, but protect them, too. Because people with cancer deserve more — more ways to treat their cancer, more quality in their lives and more time.
Blood cancers
Blood cancer is a disease that impacts blood forming tissues (such as bones marrow) and inhibits the body's ability to fight off infection. Leukemia, lymphoma, and myeloma are the most common forms of blood cancer that are seen in patients.
Solid Tumour
Despite recent innovations, people living with solid tumors are still in need of more options. As survival rates remain low, patients often run out of options after multiple cycles of treatment, emphasizing the urgent need to further improve patient care and outcomes.
We are advancing an innovative solid tumor portfolio that tackles some of the most difficult-to-treat cancers. Our approach is to target novel anti-cancer pathways, using different modalities such as antibody-drug conjugates (ADCs) designed to target protein biomarkers, which are over-expressed across various tumor types, to deliver potent cancer-killing agents called ‘payloads’ to those cells, and immuno-oncology (IO) approaches, that use the body's immune system to fight cancer.
Our oncology discovery and development efforts
Our relentless focus on achieving the next breakthrough in cancer care is inspired by the lives we aim to prolong and protect. We’re following the science to discover innovations that can help patients no matter what stage of cancer they have, or so they may never be diagnosed with some types at all.
Our three areas of focus in oncology research:
Immuno-oncology
Boosting anti-tumor responses by combining foundational cancer treatments with negative immune regulators that play different roles in adjusting the immune response.
The Promise of Cell Therapy at Genventis
Genventis is harnessing the transformative potential of cell therapies to develop innovative treatments for diseases with high unmet medical needs. By using living cells as therapeutic agents, we aim to go beyond symptom management to address the underlying causes of disease and provide durable, long-lasting benefits.
In oncology, our programs explore CAR-T cell therapy and other immune cell-based approaches designed to target and eliminate cancer cells with precision, offering hope to patients with aggressive or treatment-resistant cancers. By engineering immune cells to recognize and attack tumors, we strive to improve survival outcomes and restore quality of life.
Through rigorous research, development, and clinical investigation, Genventis is committed to advancing safe, scalable, and effective cell therapy platforms that can transform the treatment landscape and bring meaningful impact to patients in need.
Supporting the cancer community
We work with the entire oncology community — advocacy partners, health care providers, governments and industry colleagues — to create programs that help patients and caregivers on their journeys, as well as provide grants to organizations that support patients with cancer.
Stories
